Patient Engagement Solutions Market - Global Industry Insights, Analysis, Forecast to 2023
The global patient engagement solutions market is growing considerably, due to growing medical tourism and increasing cloud based models. During the forecast period, the software segment is expected to report the largest share, among all the components segments of the patient engagement solution market. Among the various delivery modes, the web based delivery segment leads the market, as it is cost effective and user friendly; however, the cloud based delivery segment is expected to grow with the fastest rate during the forecasted period. Among the various applications, the health management segment leads the global patient engagement solutions market. Based on therapeutics area, the chronic diseases segment leads the market in terms of size and is expected to grow with the fastest rate during the forecast period. Among the various end users, the providers segment led the market in 2014.
Explore Report at: https://www.psmarketresearch.com/market-analysis/patient-engagement-solutions-market
The unexplored market in the patient engagement solution industry of the developing economies is creating growth opportunities for the market players. Some of the major trends in the global market are awareness among patients about the solutions, increasing number of mergers and acquisitions, and increasing number of collaborations and partnerships. The patient engagement solutions provide various benefits, such as reduction in hospital readmission rates, cost reduction, improved quality of healthcare, and increased patient outreach.
Geographically, North America is expected to dominate the global market in the coming years, due to growing geriatric population, implementation of Affordable Care Act, and increasing prevalence of chronic diseases. Asia is expected to be the fastest growing region, due to growing medical tourism and increasing healthcare awareness in the region. In addition, the Asian market of patient engagement solutions is growing due to increasing healthcare expenditure and increasing healthcare information technology adoption in the emerging countries, such as India and China.
Ask for TOC at: https://www.psmarketresearch.com/market-analysis/patient-engagement-solutions-market/toc-sample
Some of the companies operating in the global patient engagement solutions market are Mckesson Corporation, Athenahealth Inc., Medecision Inc., Cerner Corporation, Orion Health, Aetna Inc., Emmi Solutions LLC., Allscripts Healthcare Solutions Inc., Getwellnetwork Inc., and Phytel Inc.
Candidiasis Therapeutics - Designation, Collaboration and Developments
The study analyzed that the candidiasis therapeutics pipeline comprises approximately 22 drug candidates in different stages of development.
Matinas Biopharma Holdings, Inc. is using Cochleate technology platform for the development of their drug candidates. The technology platform is a lipid-crystal nano-particle targeted drug delivery system, that offers a drug delivery solution with differentiating and disruptive features including oral availability, multi-organ protection, enhanced safety and targeted delivery to the site of the infection and inflammation along with the ability to effectively penetrate the tissues.
The research found that various companies received many designations from the U.S. Food and Drug Administration (USFDA) for the development of candidiasis therapeutics pipeline. In May 2016, USFDA granted the orphan drug designation to SCY-078 for the treatment of invasive candida infections, including candidemia.
Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/candidiasis-therapeutics-pipeline-analysis/report-sample
Some of the key players developing drugs for the treatment of candidiasis include Seren Pharmaceuticals, Inc., SCYNEXIS, Inc., Matinas Biopharma Holdings, Inc., and others.
Post-Operative Pain Therapeutics Pipeline - Patent, Designation and Other Developments
The study analyzed that the post-operative pain therapeutics pipeline comprises approximately 39 drug candidates in different stages of development. Post-operative pain is one of the most common problem experienced by a person after any surgery. The intensity of pain can vary from acute to chronic depending upon the time it lasts. It starts when pain receptors activate an electrical signal that travels to the spinal cord. The spinal cord then transmits the signal to the brain. It involves the interaction of various chemicals, known as neurotransmitters, in the body, which together act to produce the sensation of pain in a person.
Browse Report Description at: https://www.psmarketresearch.com/market-analysis/post-operative-pain-therapeutics-pipeline-analysis
Innocoll Holdings plc is using CollaRx technology platform for the development of INL-001 for the treatment of post-operative pain. The CollaRx technology platform produces a lyophilized porous matrix of purified collagen that can be implanted at the time of surgery or applied topically to chronic or acute traumatic wounds. The CollaRx matrices are biodegradable and bio-resorbable. The in vivo release of drugs incorporated into the CollaRx matrix takes place via a combination of dissolution, diffusion and the interactive characteristics of the active drug and the formulation that can be modified to affect controlled release.
Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/post-operative-pain-therapeutics-pipeline-analysis/report-sample
Some of the key players developing drugs for post-operative pain include DURECT Corporation, Elite Pharmaceuticals, Inc., Cara Therapeutics, Inc. and others.
Anti-Aging Market Size, Analysis, Growth and Forecast to 2025
According to the study, the global anti aging market is expected to witness 7.7% CAGR during 2017 – 2025. Technological advancements, increase in volume of anti-aging procedures, growing aging population and increase in disposable income have been driving the global anti-aging market. The market is further expected to gain revenue due to increase in anti-aging awareness campaigns. For instance, EuroMediCom plans to organize the 15th Aesthetic & Anti-Aging Medicine World Congress from 6th April to 8th April, 2017, in Monaco. Furthermore, EuroMediCom is also going to organize the 4th AMWC Latin America- Aesthetic & Anti-Aging Medicine World Congress from 16th November to 18th November, 2017, in Colombia, South America. EuroMediCom promotes future medical sciences, particularly those related to aging and aesthetics.
Browse Report Overview at: https://www.psmarketresearch.com/market-analysis/anti-aging-market
As per the findings of research, anti-wrinkle products, which includes dermal fillers and botox, is expected to witness considerable growth during the forecast period, primarily due to high sales of botulinum toxin and increasing appearance consciousness and awareness among women about anti-wrinkle products. Anti-wrinkle products include anti-wrinkle milk, anti-wrinkle moisturizers, anti-wrinkle creams, anti-wrinkle gels and anti-wrinkle serums. Wrinkles are formed due to lack of collagen in the body which makes the skin elastic and firm. The two main types of wrinkles include surface lines and deep furrows. Anti-wrinkle creams, oils and gels reduce fine lines, but deep furrows usually require anti-aging treatments, such as plastic surgery and botox injections. Radiofrequency, laser, anti-cellulite, and microdermabrasion devices are used for the anti-aging treatment such as hair restoration, anti-pigmentation, anti-adult acne treatment, liposuction and breast augmentation.
The anti-aging market has witnessed number of mergers and acquisitions and strategic alliances recently. In January 2017, L'Oréal signed an agreement with Valeant Pharmaceuticals to acquire its the skincare brands including, CeraVe, AcneFree and Ambi for a consideration of $1.3 billion in cash. These products are expected to expand L’Oreal’s Active cosmetics division. In July 2016, Johnson & Johnson acquired Vogue International LLC, a privately-held company focusing on marketing hair care and other personal care products, for an amount of $3.3 billion in cash. The acquisition was expected to strengthen Johnson & Johnson’s consumer segment with hair care and personal care products.
Browse Report Sample at: https://www.psmarketresearch.com/market-analysis/anti-aging-market/report-sample
Some of the other key players in the market include The Proctor & Gamble Company, Beiersdorf AG, Allergan Plc., The Estee Lauder Companies Inc., Nu Skin Enterprises, Inc., Coty Inc., Cynosure, Inc., Lumenis Ltd., Syneron Medical Ltd., Photomedex Inc., Orlane, Personal Microderm and Alma Lasers Ltd.
Medical Device Connectivity Industry Analysis, Size, Growth and Forecast to 2023
The global medical device connectivity market is witnessing considerable growth due to increasing implementation of electronic health records and health information exchange systems, increasing regulations for improving healthcare quality, growing demand for home healthcare due to increasing geriatric population, improved diagnosis of patient, and increasing healthcare IT initiatives. Moreover, increasing prevalence of chronic diseases, increasing emphasis on care quality and patient safety, and increasing need to reduce healthcare costs through a connected healthcare environment are supporting the demand of medical device connectivity. The medical device connectivity aids in data analytics and growing adoption of telehealth solutions are also driving the growth of the market. Based on product type, the market for service segment is expected to grow at the faster rate compared to solution during the forecast period, due to increasing requirement for maximum consumption of connectivity solutions by the user, increasing regulatory requirements and healthcare reforms, increasing implementation of healthcare information exchange system, and increasing need for effective implementation.
Explore Report at: https://www.psmarketresearch.com/market-analysis/medical-device-connectivity-market
The growing adoption of telehealth solutions, shift of point-of-care diagnostics from hospitals to home care and increasing need for interoperability due to medical devices connectivity solutions are some of the major trends for the global medical device connectivity market.
The increasing female aging population is propelling the growth of the global Hysteroscope market. As reported by UN DESA (United Nation Department of Economic and Social Affairs) in the year 2013, the elder population is predominantly female. As women tend to live longer than men, while older women have outnumbered older men almost everywhere in the world. It further reported that in the year 2013, globally, there were 85 men per 100 women in the age group 60 years or plus; and 61 men per 100 women in the age group 80 years or plus. The elderly population is more susceptible to gynaecological problems, such as abnormal uterine bleeding, fibroids, and polyps, as compared to adults, which is fuelling the demand of the global hysteroscope market. Aging in females leads to changes in hormones leading to irregular menses, which contributes to the demand for Geographically, North America has been the largest and fastest growing market for medical device connectivity, owing to better accessibility to technologies, increasing demand for eHealth solutions, increasing funding for innovation in medical sector, increasing focus on quality of care and patient safety, and increasing government initiatives and support in the region. The U.S. contributed largest revenue to the North American as well as global medical device connectivity market. The increasing implementation of electronic health record systems, growing geriatric population, and increasing need for data analytic in healthcare are the key growth driving factor for the U.S. medical device connectivity market.
Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/medical-device-connectivity-market/report-sample
The key players operating in the global medical device connectivity market are GE Healthcare, Cerner Corporation, Cisco Systems Inc., Qualcomm Inc., Koninklijke Philips N.V., Medtronic Plc., Infosys Limited, and Digi International Inc.
Medical Image Management Industry Analysis, Demand, Forecast to 2023
The global medical image management market is witnessing considerable growth due to technological advancements in diagnostic imaging modalities and image management solutions, increasing usage of imaging equipment, and increasing adoption of Vendor Neutral Archive (VNA). Moreover, increasing investment in the medical imaging, increasing adoption of imaging management system by small imaging centers and hospitals, and rapidly growing big data in healthcare are supporting the demand for medical image management systems. The increasing government initiatives to encourage electronic medical record adoption is further expected to boost the market. Based on product type, picture archiving and communication system (PACS) segment leads the global market in terms of size, due to technological advancements in PACS, increasing volume of imaging procedure and adoption of the PACS in new imaging segments such as mammography, endoscopy, oncology and ophthalmology. Hospitals have been the largest user of medical image management systems, owing to growing awareness about early diagnosis of diseases, increasing digitalization of patient’s data, rapid growth in adoption of EMR, and technological advancement in imaging modalities.
Explore Report at: https://www.psmarketresearch.com/market-analysis/medical-image-management-market
Rapidly increasing big data in healthcare and rapid growth in geriatric imaging volumes are also fueling the growth of the global medical image management market. Geriatric population has weakened body functions, and are more susceptible to chronic diseases. As per the United Nations Department of Economic and Social Affairs (UN-DESA) report on the global aging population, the population of people aged 60 years or above is growing with high rate. The global percentage of people aged 60 or above in 2013 was 11.7% and it is expected to reach 21.1% by the end of 2050. Further, the number of people aged 60 years and above is expected to reach approximately 437 million in China, 324 million in India, 107 million in the U.S. and 58 million in Brazil by 2050.
Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/medical-image-management-market/report-sample
The key players operating in the global medical image management market are McKesson Corporation, General Electric Company, Fujifilm Holdings Corporation, Siemens AG, IBM Corporation, Koninklijke Philips N.V. and AGFA-Gevaert Group.
Systemic Lupus Erythematosus Pipeline - Patent, Designation, Collaboration, and Other Developments
The study analyzed that the systemic lupus erythematosus pipeline comprises of 57 drug candidates in different stages of development. Systemic lupus erythematosus is a type of lupus in which the immune system damages its own tissues. The disease affects many parts of the body including skin, joints, lungs, brain, blood vessels and kidneys. The systemic lupus erythematosus is caused by impaired immune system due to which the immune system attacks its own tissues and can cause widespread inflammation and tissue damage in the affected organs. Some of the common symptoms of systemic lupus erythematosus include oral ulcers, sun sensitivity, heart problems, kidney problems, psychosis, lung problems, arthritis, seizures, fevers, skin rashes, fatigue, swelling and pain in the joints. Systemic lupus erythematosus is being treated using a combination approach as number of organs are involved. Therefore, various combination therapies are being used to improve quality of life of the patients. Also, combining novel drugs against different organs as well as combination of drugs with biological and biochemical agents may further enhance the treatment quality.
Explore Report Description at: https://www.psmarketresearch.com/market-analysis/systemic-lupus-erythematosus-pipeline-analysis
Seattle Genetics, Inc. is using antibody-drug conjugate (ADC) technology platform for the development of Brentuximab vedotin for the treatment of systemic lupus erythematosus. The technology platform employs a monoclonal antibody specific for a tumor-associated antigen, plus synthetic cytotoxic (cell-killing) agents connected by stable linker systems designed to securely bind the cytotoxic agent to the antibody and then release the agent within the targeted cell.
The research also found that various companies have collaborated for the development of systemic lupus erythematosus pipeline.
Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/systemic-lupus-erythematosus-pipeline-analysis/report-sample
Some of the key players developing drugs for systemic lupus erythematosus include Anthera Pharmaceuticals, Inc., Genentech, Inc., Merck KGaA and others.
